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Abstract Caenorhabditis elegans CLK-1 was identi¢ed from
long-lived mutant worms, and is believed to be involved in ubi-
quinone biosynthesis. The protein belongs to the eukaryotic
CLK-1/Coq7p family, which is also similar to the bacterial
Coq7 family, that hydroxylates demethoxyubiquinone, resulting
in the formation of hydroxyubiquinone, a precursor of ubiqui-
none. In Escherichia coli, the corresponding reaction is cata-
lyzed by UbiF, a member of a distinct class of hydroxylase.
Although previous studies suggested that the eukaryotic CLK-
1/Coq7 family is a hydroxylase of demethoxyubiquinone, there
was no direct evidence to show the enzymatic activity of the
eukaryotic CLK-1/Coq7 family. Here we show that the plasmid
encoding C. elegans CLK-1 supported aerobic respiration on a
non-fermentable carbon source of E. coli ubiF mutant strain and
rescued the ability to synthesize ubiquinone, suggesting that the
eukaryotic CLK-1/Coq7p family could function as bacterial
UbiF.
* 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Caenorhabditis elegans clk-1 was originally identi¢ed from
long-lived mutant worms ([1,2], reviewed in [3], references
cited therein)). The C. elegans CLK-1, localized in mitochon-
dria [4], belongs to the eukaryotic CLK-1/Coq7p family in-
cluding the Saccharomyces cerevisiae homologue Coq7p [5]
and mammalian homologues [6^8]. Some bacteria also have
the gene for the Coq7 homologue that has recently shown to
be responsible for the hydroxylation of demethoxyubiquinone
(DMQ), resulting in the formation of 5-hydroxyubiquinone, a
precursor of ubiquinone (UQ, coenzyme Q) [9]. In Escherichia
coli, the corresponding reaction is catalyzed by UbiF, a mem-
ber of a distinct class of hydroxylase [10]. Although studies of
mutants suggested the eukaryotic CLK-1/Coq7 family may
function as a hydroxylase of the precursor of UQ [5,11^14],
there was no direct evidence to show enzymatic activity which
may be present within the of eukaryotic CLK-1/Coq7 family.
Here we show that the plasmid encoding C. elegans CLK-1
supported the aerobic growth of E. coli ubiF mutant under the
condition that succinate was the sole carbon source and it
supplemented the ability to synthesize UQ, suggesting that
the eukaryotic CLK-1/Coq7p family could be functional
equivalent to bacterial UbiF, a hydroxylase of DMQ.
2. Materials and methods
2.1. Bacterial strains and plasmids
The E. coli strains and plasmids used in this study are listed in
Table 1. E. coli JF496 was from E. coli Genetic Stock Center (Yale
University, New Haven, CT, USA). Transformation of E. coli was
performed according to published protocols [15,16].
2.2. cDNA cloning of C. elegans clk-1
C. elegans strain Bristol N2 was grown and harvested as previously
described [11]. Total RNA was extracted with Trizol (Invitrogen). The
RNA was treated with DNase I (Invitrogen, USA), extracted with
phenol^chloroform^isoamylalchol (25:24:1, v/v/v), then precipitated
with ethanol. Reverse transcription of RNA (2 Wg) was carried out
with random hexamer and ReverTraAce (Toyobo, Japan) according
to the manufacturer’s instructions. Polymerase chain reaction (PCR)
reaction mixture (50 Wl) including 10% of the above cDNA product,
0.5 WM of primers P-587 (5P-CATATGTTCCGTGTAATAACCC-
GTGGAGCACATAC-3P) and P-588 (5P-GGATCCTCATCAAAT-
TTTCTCAGCAATCGCAATAGCT-3P) and 2.5 units of ExTaq (Ta-
kara Bio, Japan) was prepared according to the protocol of the
supplier of the enzyme. PCR conditions used were as follows: 30
cycles of 95‡C for 30 s, 60‡C for 30 s, and 72‡C for 1 min. The
PCR product was ligated with pCR2.1 vector without further puri¢-
cation, and then introduced into XL-1Blue. The transformants were
grown and the plasmids were extracted and veri¢ed by restriction
analysis. Sequence of the cDNA was con¢rmed with Thermo Seque-
nase primer cycle sequencing kit (Amersham Biosciences, USA) on a
DNA sequencer DSQ-2000L (Shimadzu, Japan), and with a DYE-
namic ET terminator cycle sequencing kit (Amersham Biosciences)
on a DNA sequencer 373A-18 (Applied Biosystems, USA). The
cDNA insert was excised using NdeI and BamHI, puri¢ed by agarose
gel electrophoresis followed by extraction with MagExtractor (Toyo-
bo, Japan) and cloned into between NdeI and BamHI sites of pET15b.
The resulting plasmid pET15b-clk-1 was ampli¢ed with NM522, and
then extracted. This construct was veri¢ed by using restriction analysis
and DNA sequencing as described above. The cDNA sequence with
the upstream region encoding the ribosome binding site and the cod-
ing sequence of His-tag sequence, derived from the parent pET15b,
was excised by using XbaI and BamHI, puri¢ed as described above
and inserted between the XbaI and BamHI sites of pUC19 and cloned.
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The DH5K transformant containing the resulting plasmid pUC19-clk-
1 was screened by colony PCR with P-587 and P-588, and then the
plasmid was extracted. The resulting construct was veri¢ed by restric-
tion analysis.
2.3. Cloning of E. coli ubiF
E. coli DH5K was grown and the DNA extracted according to the
standard protocols [17]. PCR reaction mixture (50 Wl) included 0.4
WM of P-766 (5P-AGCTGATATCTACAACCGGGCTGC-3P, corre-
sponding to 7362^7385 of the GenBank accession number D90706)
and P-767 (5P-CCAGGTACCCCAGCCATCAAGAAA-3P, comple-
mentary to 9541^9564 of the GenBank accession number D90706),
5 units of PfuTurbo DNA polymerase (Stratagene) and DNA (100 ng)
extracted from DH5K as the template and other components accord-
ing the protocol of the supplier of the enzyme. PCR conditions were
as follows: 1 cycle of 95‡C for 2 min, 10 cycles of 95‡C for 30 s, 65‡C
for 30 s, 72‡C for 150 s, then 25 cycles of 95‡C for 30 s, 50‡C for 30 s,
72‡C for 150 s, followed by 72‡C for 10 min. The PCR product was
puri¢ed as described above, digested with EcoRV and KpnI, and then
cloned between the HindII and KpnI sites of pUC19. The transformed
DH5K was screened by colony PCR with vector-speci¢c primers. The
resulting plasmid pUC19-ubiF was extracted, then veri¢ed by restric-
tion analysis and DNA sequencing with Prism BigDye Terminator
v3.0 cycle sequencing ready reaction kit (Applied Biosystems) on a
Prism 310 DNA genetic analyzer (Applied Biosystems). The UbiF
coding sequence of DH5K was identical to that of the published ge-
nome of E. coli K12 strains (GenBank accession numbers AE000170
and D90706).
2.4. Complementation of ubiF mutation
The plasmids pUC19, pUC19-ubiF and pUC19-clk-1 were intro-
duced into JF496. Colonies were selected on LB/kanamycin (50 Wg/
ml)/ampicillin (100 Wg/ml) or LB/kanamycin (50 Wg/ml)/carbenicillin
(100 Wg/ml, only for pUC19-containing colonies) plates by three suc-
cessive streaks on the plates. The cells were grown in 5 ml of LB/
carbenicillin/glucose (0.5%, w/v) for plasmid extraction and prepara-
tion of the glycerol stocks. They were veri¢ed for their ability to grow
on glucose minimal and succinate minimal salt media agar plates
including auxotrophic requirements according to [9,10] and carbeni-
cillin (100 Wg/ml) in place of ampicillin at 37‡C for 40 h. The strains
from the glycerol stocks were grown in LB/carbenicillin/glucose up to
A600 of 0.6^0.7, then the cells from 330 Wl of the culture were har-
vested, washed with the minimal salt medium, suspended in 330 Wl of
the minimal medium, and then 10 Wl was streaked onto a plate. For
growth in liquid minimal media, the stocks were grown, washed and
suspended as above, then 150 Wl of the suspended cells was added to
15 ml of glucose minimal or succinate minimal media including auxo-
trophic requirements according to [9,10] and carbenicillin (100 Wg/ml)
in place of ampicillin, then grown at 37‡C.
2.5. Protein and quinone analysis
For protein analysis, E. coli JF496 derivatives and DH5K were
grown in two 100 ml batches of LB/kanamycin (50 Wg/ml)/ampicillin
(100 Wg/ml) in a 500-ml Erlenmeyer £ask up to A600 of 0.6^0.7. As for
the Rosetta(DE3)pLysS/pET15b-clk-1, the cells were grown in 30 ml
of LB/carbenicillin/chloramphenicol (15 Wg/ml) in a 100-ml Erlen-
meyer £ask up to A600 of 0.1^0.2, then isopropyl-L-D-thiogalactopyr-
anoside (¢nal concentration 1 mM) was added, followed by incuba-
tion for a further 4 h (A600 1.2). The cells from 1 ml of the culture
were harvested, suspended in 50 Wl (100 Wl for Rosetta(DE3)pLysS/
pET15b-clk-1) of 50 mM Tris, mixed with 50 Wl (100 Wl for Rosetta-
(DE3)pLysS/pET15b-clk-1) of sample bu¡er (125 mM Tris^HCl, pH
6.8, 4%(w/v) sodium dodecyl sulfate (SDS), 10%(v/v) 2-mercaptoeth-
anol, 15.8%(v/v) glycerol, 0.1%(w/v) bromophenol blue), sonicated on
ice three times for 10 s with the intervals of 10 s, incubated at 90‡C for
3 min, and then 10 Wl was loaded on a 10^20% (w/v) gradient SDS^
polyacrylamide gel (Daichi Pure Chemicals, Japan). Immunoblot
analysis using anti-CLK-1 polyclonal antibodies (cC-14, Santa Cruz
Biotechnology, USA, 1:2000 dilution) was carried out according to
[18] in the presence of lysates of E. coli to reduce the reactivity to the
E. coli proteins present. For quinone analysis, the bacteria were grown
and harvested from two of 100 ml cultures, and then the membrane
fraction was prepared as described [19]. Extraction and analysis of
lipids were carried out as described [11]. The mass spectra of the
quinones were analyzed by using a Perkin Elmer Sciex API165 with
electrospray ionization (ESI).
3. Results and discussion
In the course of the biochemical study of C. elegans CLK-1,
we cloned the cDNA of clk-1 by reverse transcription fol-
lowed by PCR and constructed an expression vector
pET15b-clk-1 under the control of an inducible T7 promoter.
Using this pET15b-clk-1 with a Rosetta(DE3)pLysS strain as
a host, the overexpression of V20.2-kDa protein was ob-
served (Fig. 3A, lane 1), although the majority of the ex-
pressed protein formed inclusion bodies (not shown). In order
to improve the solubility of the protein and verify the function
of the expressed protein in E. coli, we subcloned the clk-1
cDNA into pUC19, and transformed E. coli ubiF mutant
JF496 [10,20] with the resulting plasmid pUC19-clk-1. We
also cloned the genomic DNA fragment containing wild-
type ubiF into pUC19 and obtained the plasmid pUC19-
ubiF. A similar construct pUFM4-2, which is a pUC18 deriv-
atives including the E. coli genomic fragment almost identical
to the insert of pUC19-ubiF, was shown to complement the
ubiF mutation of JF496 [10]. As a negative control plasmid,
pUC19 was used.
To see whether clk-1 cDNA complements the ubiF muta-
tion of E. coli, viability of the JF496 containing the above
plasmids on minimal medium plates with glucose or succinate
as the sole carbon source was tested (Fig. 1). On the glucose
minimal salt medium plate, all strains grew, while on the
succinate minimal salt medium, JF496/pUC19 did not grow
well but JF496/pUC19-ubiF grew well as expected. JF496/
pUC19-clk-1 also grew on the succinate minimal salt medium
plate although its growth was slower than that of JF496/
Table 1
E. coli strains and plasmids used in this study
Strains/plasmids Brief description Source/
reference
XL-1Blue cloning host Stratagene
NM522 cloning host Stratagene
DH5K cloning host, ubiFþ Invitrogen
JF496 ubiF411, asnB50: :Tn5 [20]
Rosetta(DE3)pLysS expression host Novagen
pCR2.1 TA-cloning vector Invitrogen
pET15b expression vector Novagen
pET15b-clk-1 pET15b derivative containing cDNA of C. elegans clk-1 this study
pUC19 cloning vector [29]
pUC19-clk-1 pUC19 derivative containing XbaI-BamHI fragment of pET15b-clk-1 including cDNA of C. elegans clk-1 this study
pUC19-ubiF pUC19 derivative containing EcoRV-KpnI fragment of E. coli DH5K genome DNA containing ubiF this study
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pUC19-ubiF. We also investigated growth of the strains in a
liquid minimal salt medium containing either glucose or suc-
cinate (Fig. 2). The results were similar to the minimal me-
dium plates, JF496/pUC19 grew poorly in succinate minimal
medium, while JF496/pUC19-ubiF and JF496/pUC19-clk-1
grew in both succinate minimal and glucose minimal salt me-
dia (Fig. 2). The growth of JF496/pUC19-clk-1 lagged for a
while in both glucose- and succinate-containing medium,
while JF496/pUC19 in glucose-containing medium grew ear-
lier. This was consistent with the slower growth of JF496/
pUC19-clk-1 on the minimal medium plates. These results
suggested that C. elegans clk-1 cDNA could complement
ubiF mutation in E. coli although the expression of clk-1
might have some negative e¡ect on the growth of the bacteria.
To con¢rm the expression of CLK-1 in E. coli, immunoblot
analysis of proteins from the JF496 derivatives using anti-
CLK-1 antibody was performed. As shown in Fig. 3B, a
20.2-kDa protein in JF496/pUC19-clk-1 reacted with the anti-
body (lane 6). The protein was not observed in other strains
but in the CLK-1-overexpression strain (lane 1), which corre-
sponds to the calculated molecular mass (22.6 kDa) of the
N-terminal His-tag and precursor CLK-1 sequence.
Furthermore, to see the function of the expressed protein in
E. coli, quinones extracted from membrane fraction of the
JF496 derivatives were analyzed by high-performance liquid
chromatography (HPLC) (Fig. 4). In ubiFþ DH5K, a peak at
15.2 min retention time, corresponding to UQ8 (numbers in-
dicate the isoprenoid side chain length), was observed as ex-
pected. In JF496/pUC19, a peak at about 14.5 min of reten-
tion time was observed. The result by mass spectrometry
as well as UV spectrum (not shown) suggested that the
peak corresponds to 2-octaprenyl-3-methyl-6-methoxy-1,4-
benzoquinone (DMQ8, ESI mass spectroscopy(m/z) 719.6
[M+Na]þ), which was observed in the previous studies of
the ubiF mutant [9,10,21], as well as contamination by un-
known compound(s) corresponding to a peak at about 14
min as discussed below. In both JF496/pUC19-ubiF and
JF496/pUC19-clk-1, a peak corresponding to UQ8 was ob-
served, suggesting that the plasmid-borne products function
Fig. 2. Growth of E. coli ubiF mutant derivatives in minimal salt
medium liquid culture. Broken lines: growth in glucose-containing
medium; solid lines: growth in succinate-containing medium;
squares: JF496/pUC19-ubiF ; circles: JF496/pUC19-clk-1 ; triangles:
JF496/pUC19.
Fig. 3. Expression of C. elegans CLK-1 in E. coli. A: The gel
stained with Coomassie brilliant blue. B: Immunoblot analysis with
anti-CLK-1 antibody. Extracts from Rosetta(DE3)pLysS/pET15b-
clk-1 (lane 1), DH5K (lane 3), JF496/pUC19-ubiF (lane 4), JF496/
pUC19 (lane 5) and JF496/pUC19-clk-1 (lane 6) together with the
size marker (prestained precision protein standard, Bio-Rad, lane 2)
were analyzed. The sizes of the markers are also shown.
Fig. 1. Growth of E. coli ubiF mutant derivatives on minimal salt
medium plates. A: Glucose-containing medium. B: Succinate-con-
taining medium. Lane 1: JF496/pUC19-clk-1 ; lane 2: JF496/
pUC19-ubiF ; lane 3: JF496/pUC19.
FEBS 27236 7-5-03
A. Adachi et al./FEBS Letters 543 (2003) 174^178176
as the hydroxylase/monooxygenase of DMQ8 and endogenous
E. coli UbiG methylates the 5-hydroxyUQ product of CLK-1
to UQ. In these strains, a peak at about 14 min retention time
was also observed. The peak may correspond to any of the
precursor(s) of UQ although its identity is currently unknown
and was not pursued further in this study. In summary, the
results suggested that C. elegans CLK-1 could function as the
hydroxylase of DMQ8 in E. coli, although, in C. elegans,
DMQ9 (2-methoxy-5-methyl-6-nonaprenyl-1,4-benzoquinone)
would be a putative substrate of CLK-1 [11,12].
Although functional expression in E. coli of some members
of the bacterial Coq7 family has been reported [9,22], com-
plementation of E. coli ubiF mutation by eukaryotic Coq7 was
not observed [22]. Thus, before this study, the role of the
eukaryotic CLK-1/Coq7 family as the hydroxylase of the pre-
cursor of UQ, suggested by the function of the bacterial Coq7
family, had not yet been established experimentally. Rather,
the multimeric complex formation of Saccharomyces cerevisiae
Coq7p with other proteins involved in UQ biosynthesis and
stabilization of Coq7p in the complex was proposed [23,24].
Furthermore, several genes for homologues of E. coli UbiF
are found in yeast and metazoa [10]. More recently, mitochon-
drial DNA binding activity of CLK-1 and a mouse homo-
logue was reported [25]. These studies suggested multiple
and/or alternative function(s), rather than the hydroxylase
of the precursor of UQ, of the eukaryotic CLK-1/Coq7 fam-
ily. However, in this study, for the ¢rst time, we showed
aerobic growth and UQ synthesis in an E. coli ubiF mutant
with the expression of CLK-1, a member of the eukaryotic
CLK-1/Coq7 family, suggesting that the eukaryotic CLK-1/
Coq7 family is responsible for 5-hydroxylation of the DMQ
without any other eukaryotic proteins, at least in E. coli.
CLK-1 is a mitochondrial protein [4] and the S. cerevisiae
homologue Coq7p and mouse homologue mCLK1 are found
in the matrix side of the inner mitochondrial membrane
[24,26]. The mitochondrial location of the eukaryotic CLK-
1/Coq7 family and the results of this study and genetic studies
[5,11^14] strongly suggest the function of the eukaryotic
CLK-1/Coq7 family as the hydroxylase of the UQ precursor
in mitochondria.
Although mutations of eukaryotic Coq7 accumulate the
precursor of UQ, and eukaryotic Coq7 orthologs could com-
plement the respiration of yeast COQ7 mutant [2,8] and the
slow growth of C. elegans clk-1 mutant [27], the phenotype of
the mutant between organisms vary: C. elegans clk-1 mutant
worms exhibit a slow-down in developmental and behavioral
rates [3] ; homozygotes of mclk1 knock-out mouse were em-
bryonic lethal [13,14]. The complementation of E. coli ubiF
mutation by CLK-1 in this study will open the way to inves-
tigate in more detail the role of this eukaryotic protein family,
which belongs to a di-iron carboxylate protein superfamily
[9,28], through protein function and structural analysis.
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